Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
We want to evaluate the efficacy of the glycopyrrolate and atropine for the prevention of catheter-related bladder discomfort.
The mechanism of catheter-related bladder discomfort is thought to be related to the muscarinic receptor. The adjuncts to reversal agents such as glycopyrrolate and atropine are known to block the muscarinic receptor in different ways.
We want to evaluate the efficacy of the glycopyrrolate and atropine for the prevention of catheter-related bladder discomfort.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Glycopyrrolate | Experimental | Glycopyrrolate will be administered as the adjuncts of neuromuscular blocker reversal agent. |
|
| Atropine | Active Comparator | Atropine will be administered as the adjuncts of neuromuscular blocker reversal agent. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Glycopyrrolate | Drug | Glycopyrrolate will be administered. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Catheter-related bladder discomfort | Catheter-related bladder discomfort will be measured at 1 hour postoperatively (0:none, 1:mild, 2:moderate, 3:severe). | 1 hour postoperatively |
| Measure | Description | Time Frame |
|---|---|---|
| Catheter-related bladder discomfort | Catheter-related bladder discomfort will be measured at 1 hour postoperatively (0:none, 1:mild, 2:moderate, 3:severe). | 0, 6 and 24 hour postoperatively |
| Hemodynamic parameters |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Hyun-Chang Kim, MD | Contact | 82-10-2886-2876 | onidori1979@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Hee-Pyoung Park, PhD | Seoul National University of Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Seoul National University of Hospital | Recruiting | Seoul, Korea, Republic of | South Korea |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26254585 | Derived | Kim HC, Lim SM, Seo H, Park HP. Effect of glycopyrrolate versus atropine coadministered with neostigmine for reversal of rocuronium on postoperative catheter-related bladder discomfort in patients undergoing transurethral resection of bladder tumor: a prospective randomized study. J Anesth. 2015 Dec;29(6):831-5. doi: 10.1007/s00540-015-2064-2. Epub 2015 Aug 9. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001749 | Urinary Bladder Neoplasms |
| ID | Term |
|---|---|
| D014571 | Urologic Neoplasms |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D006024 | Glycopyrrolate |
| D001285 | Atropine |
| ID | Term |
|---|---|
| D000644 | Quaternary Ammonium Compounds |
| D000588 | Amines |
| D009930 | Organic Chemicals |
| D009861 | Onium Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Atropine |
| Drug |
Atropine will be administered. |
|
Mean blood pressure and heart rate will be measured at 0, 1, 5, 10 minute postoperatively. Measurement at 10 minute means Mean blood pressure and heart rate at the admission of post-anesthetic care unit.
| 0, 1, 5, 10 minute postoperatively |
| Nausea | Nausea will be measured at 0, 1, 6 and 24 hour postoperatively. | 0, 1, 6 and 24 hour postoperatively |
| Vomiting | Vomiting will be measured at 0, 1, 6 and 24 hour postoperatively. | 0, 1, 6 and 24 hour postoperatively |
| Dry mouth | Dry mouth will be measured at 0, 1, 6 and 24 hour postoperatively. | 0, 1, 6 and 24 hour postoperatively |
| Flushing | Flushing will be measured at 0, 1, 6 and 24 hour postoperatively. | 0, 1, 6 and 24 hour postoperatively |
| Blurred vision | Blurred vision will be measured at 0, 1, 6 and 24 hour postoperatively. | 0, 1, 6 and 24 hour postoperatively |
| Dizziness | Dizziness will be measured at 0, 1, 6 and 24 hour postoperatively. | 0, 1, 6 and 24 hour postoperatively |
| Analgesics | The amount of analgesics will be measured at 0, 1, 6 and 24 hour postoperatively. | 0, 1, 6 and 24 hour postoperatively |
| D052776 |
| Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D001745 | Urinary Bladder Diseases |
| D014570 | Urologic Diseases |
| D052801 | Male Urogenital Diseases |
| D011759 |
| Pyrrolidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D001286 | Atropine Derivatives |
| D014326 | Tropanes |
| D053961 | Azabicyclo Compounds |
| D001372 | Aza Compounds |
| D001533 | Belladonna Alkaloids |
| D012991 | Solanaceous Alkaloids |
| D000470 | Alkaloids |
| D019086 | Bridged Bicyclo Compounds, Heterocyclic |
| D006572 | Heterocyclic Compounds, Bridged-Ring |